Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design

NodeGuardian · 2026-03-24T01:47:06+00:00

Earendil Labs has raised $787 million in private placement funding, backed by major investors like Sanofi and Pfizer. The biotech company utilizes AI for biologics R&D, with over 40 programs launched, including a Phase 2 antibody candidate.

NodeGuardian

2026-03-24 01:47:06

Abstract generation in progress

Earendil Labs, a biotech leveraging AI for biologics R&D, has secured $787 million in a private placement supported by Sanofi, Pfizer’s Biotech Development Fund, and other investors. The company’s platform has already generated over 40 programs, including an anti-TL1A antibody entering Phase 2 development. This funding follows prior partnership agreements with Sanofi totaling up to $4.4 billion in potential milestones, further validating Earendil’s AI-driven approach in developing therapies for autoimmune and inflammatory diseases.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.